Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
TORONTO, ONTARIO June 24, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from June 27 – 28, 2022 in New York. Braxia Scientific CEO Dr. Roger McIntyre will deliver two live presentations at the conference beginning with a Keynote address - Introduction to the State of Mental Healthcare – to kick off the conference on Monday, June 27 at 8:15 a.m. ET Dr. McIntyre, will also deliver a second presentation on Monday, June 27 at 4:00 p.m. ET providing an overview of the Braxia’s business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression, while also expanding the...
Keynote at Wonderland: Miami
Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami TORONTO, Ontario Nov. 8, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, has been selected to be a keynote speaker at the Wonderland: Miami conference. The two-day event, which is scheduled to begin Mon., Nov. 8 at the Adrienne Arsht Center for the Performing Arts of Miami-Dade County, will act as a launching pad for innovative companies connected to the psychedelic medicine space. Dr. McIntyre will discuss the challenges patients with medication-resistant mental health issues face in accessing ketamine and other psychedelic therapies as well as developing new therapies. He will also outline...
Graduates First Cohort of Medical Professionals
Braxia Scientific Graduates First Cohort of Medical Professionals From Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial TORONTO, ONTARIO November 2, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is excited to announce the completion of the training program for psilocybin-assisted clinical therapy by its first multi-disciplinary cohort of 20 qualified therapists from diverse psychiatry and psychotherapy backgrounds. This program was implemented by the Braxia Institute, the Company’s training centre focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy. Through this program, the Company is able to develop, train, and support qualified, independent medical physicians, psychologists and psychotherapists skilled in best practices to implement safe and...
Audio Webcast and Dial-In Number
Braxia Scientific Provides New Audio Webcast and Dial-In Number for Annual General Meeting TORONTO, ONTARIO, October 27, 2021 /CNW/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today provides revised details in connection with its annual general meeting of shareholders to be held on October 28, 2021, at 10:00 am (EST). The Company advises that the audio webcast and dial-in number for shareholders wishing to listen to the meeting have been changed from those provided in the notice of annual general meeting and information circular of the Company. The updated audio webcast and dial-in number is below: Audio Webcast Link: Click here for secure access Phone Number: +1-844-974-2903 Meeting Number: 2345 – 825 – 5938 Password: meet2021 Access Code: 234 – 582...
NBA Champion Lamar Odom
Braxia Scientific CEO Dr. Roger McIntyre to Share Stage With NBA Champion Lamar Odom and ‘Psychedelic Concierge’ Zappy Zapolin to Discuss the Benefits of Ketamine Treatment for Mental Health Panel discussion on November 9 at Wonderland: Miami will review the benefits of ketamine treatment for depression and other mental health conditions TORONTO, ONTARIO October 14, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its CEO, Dr. Roger McIntyre, will join fellow VIPs Lamar Odom and Zappy Zapolin for a panel discussion entitled “Ketamine Treatment Goes Mainstream” at the Wonderland: Miami conference on November 9, 2021. The two-day event, which is scheduled to begin November 8 at the Adrienne Arsht Center for the Performing...
Canaccord Genuity
Canaccord Genuity 41st Annual Growth Conference Registration for Canaccord Genuity 41st Annual Growth Conference Click here Symbols – CSE: BRAX OTC: BRAXF FWB: 496
Global Investment Conference
H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Registration for H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Click here Symbols – CSE: BRAX OTC: BRAXF FWB: 496
CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...
EXPERIMENTAL MEDICINE IN PSYCHIATRY
BRAXIA SCIENTIFIC TO DISCUSS PSYCHIATRIC TREATMENT DISCOVERY AND DEVELOPMENT WITH OXFORD UNIVERSITY RESEARCHERS AT AIMDAY EXPERIMENTAL MEDICINE IN PSYCHIATRY ON JULY 7, 2021 TORONTO, ONTARIO July 7, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research and development company along with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Academic Industry Meeting Day (AIMday) on “Experimental Medicine in Psychiatry,” hosted by Oxford University on Wednesday, July 7, 2021. Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of “How can we advance treatment discovery and development in psychiatry targeting cognition?” They will describe how research will be conducted with ketamine and psychedelics that integrates machine-learning, proof-of-mechanism research and implementation science which will be critical for the...
PSYCH INVESTOR SUMMIT
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT PSYCH INVESTOR SUMMIT ON JULY 7, 2021 TORONTO, ONTARIO July 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will be held virtually on July 7, 2021. Braxia CEO Dr. Roger McIntyre will deliver a presentation discussing the recently announced funding by the Canadian Institutes Of Health Research (CIHR), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression. Additionally, Dr. McIntyre will discuss Braxia’s initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics. The presentation will...
TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021
Braxia Institute Psilocybin-Assisted Therapy Training Program Request for Applications for Class of 2022 Application Deadline: July 11, 2021 Tentative Program Start Date: September 2021 (pandemic permitting) A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical...
ENROLLMENT FOR SEPTEMBER 2021
BRAXIA INSTITUTE TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021 Braxia Institute Psilocybin-Assisted Therapy Training Program Request for Applications for Class of 2022 A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical care, if psilocybin...